Module 1: Evidence-Based Recommendations
Chronic pain affects 100 million Americans. Certain patients with chronic pain are candidates for intrathecal (IT) therapy, which can mitigate some of the risks associated with systemic opioids. Following appropriate patient selection based on medical and psychiatric history and a physical exam, a patient can begin a trial with morphine or ziconotide, the 2 US Food and Drug Administration (FDA)–approved IT therapies. Monitoring for adverse events should continue after IT pump implantation, as should monitoring for catheter- or pump-related complications. This CME-accredited Point of Care 201™ 2-part series discusses identification of candidates for IT therapy, available IT therapies, optimal treatment initiation and management, and both surgical implantation and pump refill techniques.
This activity has been designed to meet the educational needs of interventional pain specialists, interventional pain fellows and residents, and other physician specialists with a focus on managing patients with severe cancer-related or chronic noncancer pain.
Upon completion of this activity, participants will be better able to do the following:
- Discuss the analgesic mechanisms of action, clinical trial data, published real-world outcomes, and prescribing considerations for intrathecal analgesics with FDA approvals to treat severe chronic pain
- Implement 2017 Polyanalgesic Consensus Conference (PACC) guidelines on identifying candidates for long-term treatment with intrathecally infused analgesics, medication selection algorithms, preimplantation trialing, and long-term optimization of efficacy and safety
|Click here to be taken to Module 2|
Timothy R. Deer, MD, DABPM
Yeshvant A. Navalgund, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of these educational activities.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of these CME activities:
|Name of Faculty or Presenter|
Relationship Identified With:
|Timothy R. Deer, MD, DABPM|
Consultant/Advisor: Abbott Laboratories, Axonics Modulation Technologies, Inc., Flowonix Medical Inc., Inc., Mainstay Medical Limited, Nalu Medical, Inc., Saluda Medical Pty. Ltd., SpineThera, Inc., Vertiflex Inc., Vertos Medical Inc.
Speakers’ Bureau: Jazz Pharmaceuticals, Inc.
Grant/Research: Abbott Laboratories, Mainstay Medical Limited, Saluda Medical Pty. Ltd., Vertiflex Inc.
Royalties, patents: Abbott Laboratories
Stock Ownership: Axonics Modulation Technologies, Inc., Nalu Medical, Inc., Saluda Medical Pty. Ltd., SpineThera, Inc., Vertiflex Inc., Vertos Medical Inc.
|Yeshvant A. Navalgund, MD|
Consultant/Advisor: Jazz Pharmaceuticals, Inc., Medtronic plcSpeakers’ Bureau: Jazz Pharmaceuticals, Inc., Medtronic plc
Non-faculty: Gena Dolson, MS; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouses/life partners have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Jazz Pharmaceuticals, Inc.
Jointly provided by the Elsevier Office of Continuing Medical Education and Integritas Communications.
CME Credit (Physicians)
These activities have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integritas Communications. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates each enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in each activity.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The Elsevier Office of Continuing Medical Education, Integritas Communications, and Jazz Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 0.50 AMA PRA Category 1 Credit(s)™
- 0.50 Non-physician